Expanded access to car-t therapy for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This program provides access to an experimental CAR-T cell therapy called cilta-cel for people with multiple myeloma who have run out of other good options. It is designed for those who qualify for the standard treatment but need special handling because their cell product is out of specification.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that is serious or life-threatening.
- You are already eligible for treatment with cilta-cel (a special type of immune cell therapy) according to the approved U.S. guidelines.
- Your doctor has decided that re-collecting your cells, re-making the treatment, or trying other anti-myeloma medicines is not a good option for you.
- Both Janssen (the drug company) and your doctor agree that this treatment is likely to help you more than harm you.
- You can give informed consent (understand and agree to the program's details).
- If you are a woman who could become pregnant, you must have a negative pregnancy test before starting the conditioning chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.